Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03704467
Title Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.

fallopian tube cancer

peritoneum cancer

ovary epithelial cancer


Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin

Avelumab + Berzosertib + Carboplatin

Age Groups: senior | adult
Covered Countries USA | BEL

No variant requirements are available.